10-Q: Haemonetics Reports Strong Revenue Growth in Q3, Completes OpSens Acquisition

Haemonetics Corporation reports a 10.1% increase in net revenues for the third quarter of fiscal year 2024, driven by growth in Plasma and Hospital segments, and completes the acquisition of OpSens, Inc.

Summary

• Haemonetics Corporation's net revenues increased by 10.1% to $336.25 million in the third quarter of fiscal year 2024, compared to $305.30 million in the same period last year.
• The company's gross profit also saw a rise, reaching $177.87 million, a 12.1% increase from $158.71 million in the prior year's quarter.
• Operating income for the quarter was $45.98 million, a 6.2% increase compared to $43.28 million in the same quarter of the previous year.
• Net income for the quarter was $31.24 million, a decrease of 5.2% compared to $32.94 million in the same quarter of the previous year.
• The company completed the acquisition of OpSens, Inc. on December 12, 2023, for a total consideration of approximately $254.5 million, net of cash acquired.
• The company incurred $6.6 million of acquisition-related costs for the nine months ended December 30, 2023.
• Haemonetics also announced plans to end of life the ClotPro analyzer system and whole blood inline collection products, incurring $8.04 million in restructuring costs for the nine months ended December 30, 2023.
• The company's effective tax rate for the three months ended December 30, 2023 was 29.0%, and 24.3% for the nine months ended December 30, 2023.
• The company's cash and cash equivalents decreased to $193.98 million as of December 30, 2023, from $284.47 million as of April 1, 2023.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with strong revenue growth and strategic acquisitions, but also highlights some challenges such as decreased net income and restructuring costs. The sentiment is positive but tempered by these factors.

Positives

• The Plasma business unit saw a revenue increase of 8.4% in Q3 and 16.8% for the nine months ended December 30, 2023.
• The Hospital business unit experienced a significant revenue increase of 23.9% in Q3 and 16.7% for the nine months ended December 30, 2023.
• The acquisition of OpSens expands the Hospital business unit portfolio in the interventional cardiology market.
• The company is in compliance with leverage and interest coverage ratios specified in its credit facilities.

Negatives

• Net income decreased by 5.2% in Q3 2024, to $31.24 million.
• The Blood Center business unit experienced a revenue decrease of 3.9% in Q3 and 3.2% for the nine months ended December 30, 2023.
• The company incurred $6.6 million in acquisition-related costs.
• Cash and cash equivalents decreased by $90.49 million during the nine months ended December 30, 2023.
• The company recorded an intangible asset impairment charge of $10.4 million related to the enicor GmbH acquisition.

Risks

• The company faces risks related to demand and market acceptance of new and existing products.
• There are risks associated with product quality, safety concerns, and potential recalls.
• The company is exposed to security breaches of its information technology systems.
• Pricing pressures from healthcare cost containment and consolidation among providers pose a risk.
• Disruptions to the supply chain and manufacturing operations could impact the company.
• The company faces risks related to the integration of OpSens and other acquisitions.
• The company is exposed to foreign currency and interest rate fluctuations.
• The company is subject to legal proceedings and litigation claims.

Future Outlook

The company expects to incur aggregate charges between $95 million and $105 million by the end of fiscal 2025 under the Operational Excellence Program. The company expects that CSL will continue to provide a meaningful contribution to our Plasma business revenue in fiscal 2025.

Management Comments

• Management uses non-GAAP financial measures to monitor the financial performance of the business, make informed business decisions, establish budgets and forecast future results.
• Management measures and evaluates the operating segments based on operating income.
• Management excludes certain corporate expenses from segment operating income.

Industry Context

The acquisition of OpSens expands Haemonetics' presence in the interventional cardiology market, aligning with the trend of medical device companies seeking growth through strategic acquisitions. The company's focus on Plasma and Hospital segments reflects the increasing demand for blood and plasma products and advanced medical technologies.

Comparison to Industry Standards

• Haemonetics' revenue growth of 10.1% in Q3 2024 is above the average growth rate for the medical device industry, which is estimated to be around 5-7%.
• The company's gross profit margin of 52.9% is within the typical range for medical device companies, which generally fall between 50% and 60%.
• The company's operating income margin of 13.7% is slightly below the average for the medical device industry, which is typically around 15-20%.
• The company's net income margin of 9.3% is also slightly below the industry average, which is typically around 10-15%.
• Compared to competitors such as Baxter and Medtronic, Haemonetics' revenue growth is stronger, but its profitability metrics are slightly lower.
• The acquisition of OpSens is similar to other strategic acquisitions in the medical device industry, such as Medtronic's acquisition of Mazor Robotics, which aim to expand product portfolios and market reach.

Legal Proceedings

• The company is involved in a qui tam action, which was unsealed on August 18, 2022, and has entered into an agreement with the individual plaintiffs to settle certain unrelated employment matters and release those individuals claims.
• The company is involved in a putative class action complaint in the Circuit Court of Cook County, Illinois, related to the Illinois Biometric Information Privacy Act (BIPA), and has recorded an additional loss contingency related to this matter.

Stakeholder Impact

• Shareholders will benefit from the company's revenue growth and strategic acquisitions.
• Employees may be affected by the company's restructuring initiatives.
• Customers will benefit from the company's expanded product portfolio and improved solutions.
• Suppliers may be affected by the company's supply chain management and cost-cutting measures.
• Creditors will be reassured by the company's compliance with debt covenants.

Next Steps

• The company will continue to integrate OpSens into its Hospital business unit.
• The company will continue to execute its Operational Excellence Program.
• The company will continue to monitor inflationary pressures and raw material costs.
• The company will continue to manage its exposure to foreign currency fluctuations.

Key Dates

Keywords

Haemonetics, OpSens, acquisition, revenue, plasma, hospital, medical devices, financial results, restructuring, interventional cardiology